Anxiety and Parkinson's disease

Primary Psychiatry

Volumn 12, Issue 7, 2005, Pages 63-68

  Menza, Matthew ^a   Dobkin, Roseanne DeFronzo ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CITALOPRAM; CLOZAPINE; GABAPENTIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ANXIETY DISORDER; BEHAVIOR THERAPY; COGNITIVE THERAPY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ELDERLY CARE; EXERCISE; GENERALIZED ANXIETY DISORDER; HEART DISEASE; HUMAN; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; PANIC; PARKINSON DISEASE; PSYCHOTHERAPY; REVIEW; SOCIAL PHOBIA; SYMPTOMATOLOGY; TREMOR;

EID: 22544470560     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. de Rijk MC, Launer LJ, Berger K, et al, for the Neurologic Diseases in the Elderly Research Group. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurology. 2000;54(11 suppl 5): S21-S23.
2. Beekman AT, Bremmer MA, Deeg DJ, et al. Anxiety disorders in later life: a report from the Longitudinal Aging Study Amsterdam. Int J Geriatr Psychiatry. 1998;13(10):717-726.
3. Regier DA, Boyd JH, Burke JD Jr, et al. One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry. 1988;45(11):977-986.
4. Stein MB, Heuser IJ, Juncos JL, Uhde TW. Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry. 1990;147(2):217-220.
5. Menza MA, Robertson-Hoffman DE, Bonapace AS. Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry. 1993;34(7):465-470.
6. Marsh L. Anxiety disorders in Parkinson's disease. Int Rev Psychiatry. 2000;12:307-318.
7. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
8. Gonera EG, van't Hof M, Berger HJ, van Weel C, Horstink MW. Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord. 1997;12(6):871-876.
9. Henderson R, Kurlan R, Kersun JM, Como P. Preliminary examination of the comorbidity of anxiety and depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1992;4(3):257-264.
10. Lauterbach EC, Duvoisin RC. Anxiety disorders in familial parkinsonism. Am J Psychiatry. 1991;148(2):274.
11. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord. 2000;15(4):669-677.
12. Weisskopf MG, Chen H, Schwarzschild MA, Kawachi I, Ascherio A. Prospective study of phobic anxiety and risk of Parkinson's disease. Mov Disord. 2003;18(6):646-651.
13. Menza MA, Mark MH. Parkinson's disease and depression: the relationship to disability and personality. J Neuropsychiatry Clin Neurosci. 1994;6(2):165-169.
14. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed rev. Washington, DC: American Psychiatric Association; 1987.
15. Schiffer RB, Kurlan R, Rubin A, Boer S. Evidence for atypical depression in Parkinson's disease. Am J Psychiatry. 1988;145(8):1020-1022.
16. Myers JK, Weissman MM, Tischler GL, et al. Six-month prevalence of psychiatric disorders in three communities 1980 to 1982. Arch Gen Psychiatry. 1984;41(10):959-967.
17. Wells KB, Golding JM, Burnam MA. Psychiatric disorder in a sample of the general population with and without chronic medical conditions. Am J Psychiatry. 1988;145(8):976-981.
18. Brown RG, MacCarthy B. Psychiatric morbidity in patients with Parkinson's disease, Psychol Med. 1990;20(1):77-87.
19. Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D. "Panic attacks" in Parkinson's disease. A long-term complication of levodopa therapy. Acta Neurol Scand. 1993;87(1):14-18.
20. Richard IH, Schiffer RB, Kurlan R. Anxiety and Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1996;8(4):383-392.
21. Rubin AJ, Kurlan R, Miller C, Shoulson I. Atypical depression and Parkinson's disease. Ann Neurol. 1986;20:150.
22. Marsh L, Solvasson B, Cahn DA, et al. Psychiatric outcome after pallidotomy for Parkinson's disease. Biol Psychol. 1997;41:107S.
23. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord. 2002;8(3):193-197.
24. Hamilton M. The assessment of anxiety status by rating. Br J Med Psychol. 1959;32:50-55.
25. Berrios GE, Campbell C, Politynska BE. Autonomic failure, depression and anxiety in Parkinson's disease. Br J Psychiatry. 1995;166(6):789-792.
26. Leentjens AF, Verhey FR, Lousberg R, Spitsbergen H, Wilmink FW. The validity of the Hamilton and Montgomery-As berg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease. Int J Geriatr Psychiatry. 2000;15(7):644-649.
27. Bowling A. Health related quality of life: a discussion of the concept, its use, and measurement. In: Bowling A, ed. Measuring Disease: A Review of Disease-Specific Quality of Life Measurement Scales. Buckingham, UK: Open University Press; 1995:1-19.
28. de Beurs E, Beekman AT, van Balkom AJ, Deeg DJ, van Dyck R, van Tilburg W. Consequences of anxiety in older persons: its effect on disability, well-being and use of health services. Psychol Med. 1999;29(3):583-593.
29. Creed F, Morgan R, Fiddler M, Marshall S, Guthrie E, House A. Depression and anxiety impair health-related quality of life and are associated with increased costs in general medical inpatients. Psychosomatics. 2002;43(4):302-309.
30. Schrag A, Selai C. Medical and psychosocial determinants of quality of life in parkinson's disease. In: Bedard MA, Agid Y, Chouinard S, et al, eds. Mental and Behavioral Dysfunction in Movement Disorders. Totowa, NJ: Humana Press Inc; 2003:501-526.
31. Marinus J, Leentjens AF, Visser M, Stiggelbout AM, van Hilten JJ. Evaluation of the hospital anxiety and depression scale in patients with Parkinson's disease. Clin Neuropharmacol. 2002;25(6):318-324.
32. Marinus J, Visser M, Martinez-Martin P, van Hilten JJ, Stiggelbout AM. A short psychosocial questionnaire for patients with Parkinson's disease: the SCOPA-PS. J Clin Epidemiol. 2003;56(1):61-67.
33. Chrischilles EA, Rubenstein LM, Voelker MD, Wallace RB, Rodnitzky RL. Linking clinical variables to health-related quality of life in Parkinson's disease. Parkinsonism Relat Disord. 2002;8(3):199-209.
34. Sinoff G, Werner P. Anxiety disorder and accompanying subjective memory loss in the elderly as a predictor of future cognitive decline. Int J Geriatr Psychiatry. 2003;18(10):951-959.
35. Beatty WW, Ryder KA, Gontkovsky ST, Scott JG, McSwan KL, Bharucha KJ. Analyzing the subcortical dementia syndrome of Parkinson's disease using the RBANS. Arch Clin Neuropsychol. 2003;18(5):509-520.
36. Richard IH, Justus AW, Kurlan R. Relationship between mood and motor fluctuations in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2001;13(1):35-41.
37. Maricle RA, Nutt JG, Valentine RJ, Carter JH. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study. Neurology. 1995;45(9):1757-1760.
38. Nissenbaum H, Quinn NP, Brown RG, et al. Mood swings associated with the 'on-off' phenomenon in Parkinson's disease. Psychol Med. 1987;17(4):899-904.
39. Menza MA, Sage J, Marshall E, Cody R, Duvoisin R. Mood changes and "on-off" phenomena in Parkinson's disease. Mov Disord. 1990;5(2):148-151.
40. Siemers ER, Shekhar A, Quaid K, Dickson H. Anxiety and motor performance in Parkinson's disease. Mov Disord. 1993;8(4):501-506.
41. Flint AJ. Generalised anxiety disorder in elderly patients: epidemiology, diagnosis and treatment options. Drugs Aging. 2005;22(2):101-114
42. Clayton PJ. The comorbidity factor: establishing the primary diagnosis in patients with mixed symptoms of anxiety and depression. J Clin Psychiatry. 1990;51(suppl):35-39.
43. Lauderdale SA, Sheikh JI. Anxiety disorders in older adults. Clin Geriatr Med. 2003;19(4):721-741.
44. Kessler RC, DuPont RL, Berglund P, Wittchen HU. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry. 1999;156(12):1915-1923.
45. Henderson R, Kurlan R, Kersun JM, Como P. Preliminary examination of the comorbidity of anxiety and depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1992;4(3):257-264.
46. Brooks DJ, Doder M. Depression in Parkinson's disease. Curr Opin Neurol. 2001;14(4):465-470.
47. Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord. 2001;16(3):507-510.
48. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry. 1992;149(4):443-454.
49. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol. 1987;45:19-34.
50. Agid Y, Cervera P, Hirsch E, et al. Biochemistry of Parkinson's disease 28 years later: a critical review. Mov Disord. 1989;4(suppl 1):S126-S144.
51. Schiffer RB. Anxiety disorders in Parkinson's disease: insights into the neurobiology of neurosis. J Psychosom Res. 1999;47(6):505-508.
52. Kurlan R, Lichter D, Schiffer RB. Panic/anxiety in Parkinson's disease: yohimbine challenge. Neurology. 1989;39:421.
53. Mayeux R, Stern Y, Williams JB, Cote L, Frantz A, Dyrenfurth I. Clinical and biochemical features of depression in Parkinson's disease. Am J Psychiatry. 1986;143(6):756-759.
54. Plomin R, Owen MJ, McGuffin P. The genetic basis of complex human behaviors. Science. 1994;264(5166):1733-1739.
55. Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274(5292):1527-1531.
56. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301(5631):386-389.
57. Menza MA, Palermo B, DiPaola R, Sage JI, Ricketts MH. Depression and anxiety in Parkinson's disease: possible effect of genetic variation in the serotonin transporter. J Geriatr Psychiatry Neurol. 1999;12(2):49-52.
58. Marsh L, Vaughan C, Schretlen D, Brandt J, Mandir AS. Psychomotor aspects of mood disorders in Parkinson's disease. Biol Psychol. 2000;47:165S.
59. Menza M, Marin H, Kaufman K, Mark M, Lauritano M. Citaloprarn treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci. 2004;16(3):315-319.
60. Russell JM, Koran LM, Rush J, et al. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety. 2001;13(1):18-27.
61. Lenze EJ, Pollock BG, Shear MK, Mulsant BH, Bharucha A, Reynolds CF 3rd. Treatment considerations for anxiety in the elderly. CNS Spectr. 2003;8(12 suppl 3):6-13.
62. Weintraub D, Depression in Parkinson's disease. Primary Psychiatry. 2005;12(7):45-49.
63. Suchowersky O, deVries JD. Interaction of fluoxetine and selegiline. Can J Psychiatry. 1990;35(6):571-572.
64. Jermain DM, Hughes PL, Follender AB. Potential fluoxetine-selegiline interaction. Ann Pharmacother. 1992;26(10):1300.
65. Ludwig CL, Weinberger DR, Bruno G, et al. Buspirone, Parkinson's disease, and the locus ceruleus. Clin Neuropharmacol. 1986;9(4):373-378.
66. Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G. Buspirone in levodopa induced dyskinesias. Clin Neuropharmacol. 1994;17(1):73-82.
67. Gorman JM. Treating generalized anxiety disorder. J Clin Psychiatry. 2003;64(suppl 2):24-29.
68. Gleason PP, Schulz R, Smith NL, et al. Correlates and prevalence of benzodiazepine use in community-dwelling elderly. J Gen Intern Med. 1998;13(4):243-250.
69. Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry. 2001;158(6):892-898.
70. Hanlon JT, Horner RD, Schmader KE, et al. Benzodiazepine use and cognitive function among community-dwelling elderly. Clin Pharmacol Ther. 1998;64(6):684-692.
71. Stanley MA, Averill PM. Strategies for treating generalized anxiety in the elderly. In: Duffy M, ed. Handbook of Psychotherapy and Counseling with Older Adults. New York, NY: John Wiley & Sons; 1997:511-525.
72. Stanley MA, Diefenbach GJ, Hopko DR. Cognitive behavioral treatment for older adults with generalized anxiety disorder. A therapist manual for primary care settings. Behav Modif. 2004;28(1):73-117.
73. Barrowclough C, King P, Colville J, Russell E, Burns A, Tarrier N. A randomized trial of the effectiveness of cognitive-behavioral therapy and supportive counseling for anxiety symptoms in older adults. J Consult Clin Psychol. 2001;69(5):756-762.
74. Wetherell JL, Gatz M, Craske MG. Treatment of generalized anxiety disorder in older adults: J Consult Clin Psychol. 2003;71(1):31-40.
75. Dunn AL, Trivedi MH, O'Neal HA. Physical activity dose-response effects on outcomes of depression and anxiety. Med Sci Sports Exerc. 2001;33(6 suppl):S587-S597.
76. Baatile J, Langbein WE, Weaver F, Maloney C, Jost MB, Effect of exercise on perceived quality of life of individuals with Parkinson's disease. J Rehabil Res Dev. 2000;37(5):529-534.
77. Higginson CI, Fields JA, Troster AI. Which symptoms of anxiety diminish after surgical interventions for Parkinson disease? Neuropsychiatry Neuropsychol Behav Neurol. 2001;14(2):117-121.
78. Martinez-Martin P, Valldeoriola F, Tolosa E, et al. Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson's disease. Mov Disord. 2002;17(2):372-377.